A panel of federal judges will convene in December to decide whether to consolidate individual lawsuits focusing on the link between the diabetes drug Actos and instances of bladder cancer into multidistrict litigation. The U.S. Judicial Panel on Multidistrict Litigation will begin hearing arguments Dec. 1 in a Savannah, Georgia, court regarding a motion to centralize Actos lawsuits filed by those who allege they developed bladder cancer as a result of using the prescription medication. The Mobile, Alabama, product liability attorneys at Long & Long are currently investigating claims from Actos users who suffer from bladder cancer. The drug has also been linked to other complications, including diabetic macular edema and heart failure. Numerous lawsuits have already been filed in district courts across the United States on behalf of individuals who were diagnosed with bladder cancer after taking the drug for at least 12 months. The lawsuits allege that Actos maker Takeda Pharmaceuticals failed to provide adequate warnings regarding potential side-effects, including an increased risk for bladder cancer. If the judicial panel agrees to establish multidistrict litigation, all individual lawsuits involving allegations that Actos led to bladder cancer would be heard by the same judge. Actos is intended to help control type 2 diabetes, the most common form of diabetes, and was approved by the Food and Drug Administration (FDA) in 1999. If you are an Actos patient who developed bladder cancer, please contact the Mobile, Alabama, dangerous drug attorneys at Long & Long for your free case evaluation.